Rad Source Technologies Rad Source
Irradiation Without Radioactive Isotopes
HOME PRODUCTS ABOUT CONTACT

Rad Source Technologies, Inc.

6825 Shiloh Road East Ste B-2

Alpharetta, GA 30005

Phone: 770.887.8669

Fax: 678.302.7510

info@radsource.com
Rad Source Technologies, Inc. Equipment has been purchased and installed in the following countries
  • United States of America
  • Mexico
  • United Kingdom
  • Israel
  • Germany
  • France
  • Italy
  • Switzerland
  • Panama
  • Taiwan


Select published papers referencing Rad Source Technologies, Inc. equipment:

The Journal of Immunology, 2004, 172: 5222-5229.
Copyright © 2004 by The American Association of Immunologists
Passive and Active Mechanisms Trap Activated CD8+ T Cells in the Liver
Beena John and Ian Nicholas Crispe
Published online February 13, 2006 doi:10.1084/jem.20051775
© Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 203, Number 2, 437-447
Complete differentiation of CD8+ T cells activated locally within the transplanted liver
Ingo Klein and Ian Nicholas Crispe
Published Online: 26 Sep 2005
Molecular Carcinogenesis, Volume 44, Issue 3 , Pages 174 - 182
Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR
Elangovan Thavathiru, John H. Ludes-Meyers, Michael C. MacLeod, C. Marcelo Aldaz
Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Science Park- Research Division, Smithville, Texas
[Cancer Research 65, 9741-9750, November 1, 2005]
© 2005 American Association for Cancer Research
Cell and Tumor Biology
Pericytes and Endothelial Precursor Cells: Cellular Interactions and Contributions to Malignancy
Rebecca G. Bagley, William Weber, Cecile Rouleau and Beverly A. Teicher
TRANSFUSION 2000;40(suppl):154S
A Simple and Effective Implementation of an X-Ray Source Blood Component Irradiator
N L Gurney, Indiana Blood Center, Indianapolis, IN
Transfusion 2000; 40(Suppl):157S
X-Ray Radiation as an Alternative to Gamma Radiation for Irradiation of Blood Components
S C Dinwiddie, W Yaddock, D O Johnson, C Tretter, W Redmond, K A Nelson, Puget Sound Blood Center Seattle, WA


About Rad Source


The Company, a Florida corporation, has been researching, developing, and producing non-isotope irradiation equipment since 1997. Its first product, the RS 3000 X-ray Blood Irradiator is a medical product used in hospital and blood banks around the world for the irradiation of human blood to combat Graft Versus Host Disease (GVHD), a frequently fatal disease to immune deficient patients. This unique, patented device is the only medical, non-isotope machine allowed by the U.S. FDA specifically for GVHD. The Company's success with this equipment resulted in installations throughout the United States and, in 2003 an exclusive licensing agreement with MDS Nordion. MDS Nordion is the world leader in blood irradiation equipment and now produces and distributes this device throughout the world.

Adapting its previous technology for the laboratory research market, the Company has been producing the RS 2000 since 1999. The RS 2000's primary application is public and private research institutions performing cell, small animal and selected test application studies. These products are currently in use at various research institutions around the world. Again, this product makes use of patented technology to deliver a uniform and consistent dose satisfying the exacting needs of researchers.

The Company's constant research and cooperative collaboration with Universities and private technology companies produced a very high output, non-isotope, x-ray emitter (patent applied for). In 2004, the Company delivered its first product using this technology. This emitter allows for equipment configurations that compare favorably with dose rates found in high dose rate self shielded cobalt irradiators. A single emitter is capable of dose rates of 150 Gy per minute and multiple emitter combinations can reach 300 Gy per minute with a high degree of uniformity and load capacities of 6 liters of density 1 material.

With the development of the 4pi emitter Rad Source has been invited to present the technology at the IAEA, the National Academy of Sciences panel on self contained sources and various seminars.

The Company recently opened a new production facility in a commercial complex located in Alpharetta, Georgia where engineering, integration, and final testing are performed. For its size, the Company has significant resources available, having worked with several engineering and integration companies in the past as well as government and University institutions. The Company's service and support is generally performed directly from the factory, with travel available as needed. In addition, the Company utilizes local technicians in select areas, but will always have available an in-house expert where necessary.

Rad Source's experience and knowledge of irradiation sources and efficiently producing irradiation as well as the support necessary to it including dosimetry, shielding and knowledge of associated regulations provides a basis of credibility for practically expanding the use of irradiation in both existing and new markets.




Select User References

Available upon request. Click here to request references.

  © 2007 Rad Source Technologies, Inc. All rights reserved.